Browse by Title

0 results found.

Type here to filter the list

A
A Multi-Institutional Analysis of Textbook Outcomes Among Patients Undergoing Cytoreductive Surgery for Peritoneal Surface Malignancies (PM14)

Favorite

Jason T. Wiseman, MD, MSPH – The Ohio State University ### 915802###Oral Abstract Presenter PM14
A Novel Preoperative Risk Score to Optimize Patient Selection for Performing Concomitant Liver Resection with Cytoreductive Surgery/HIPEC (PM15)

Favorite

Rachel M. Lee, MD, MSPH – Winship Cancer Institute, Emory University ### 915774###Oral Abstract Presenter PM15
A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology (CT2)

Favorite

Brian Badgwell, MD, MS – MD Anderson ### 915754###Oral Abstract Presenter CT2
A Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases (HPB1)

Favorite

G. Paul Wright, MD – Spectrum Health/Michigan State University ### 915803###Oral Abstract Presenter HPB1
An Immune Tolerant Sentinel Node Microenvironment Predicts Recurrence in Melanoma (M2)

Favorite

Norma E. Farrow, MD – Duke University ### 915760###Oral Abstract Presenter M2
Applied Research Session 1

Favorite

Mohammad Haroon A. Choudry, MD – University of Pittsburgh School of Medicine ### 915757###Moderator @@@ Maheshwari Senthil, MD – Loma Linda University Health ### 915794###Moderator
Applied Research Session 2

Favorite

Chukwuemeka Ihemelandu, MD – MedStar Georgetown University Hospital ### 915767###Moderator @@@ Mustafa Raoof, MD – City of Hope National Medical Center ### 915788###Moderator
B
Billing for HIPEC

Favorite

Kiran K. Turaga, MD, MPH – University of Chicago ### 894418###Speaker#########
Speaker: Kiran K. Turaga, MD, MPH – University of Chicago
Bringing the Heat: The Challenges and Opportunities of Starting a HIPEC Program

Favorite

H. Richard Alexander, Jr., MD – Rutgers Cancer Institute ### 917895###Moderator
Building a Network: Committees, Boards, and Influence

Favorite

David L. Bartlett, MD – University of Pittsburgh School of Medicine ### 917897###Speaker
Building a Successful Practice

Favorite

Kiran K. Turaga, MD, MPH – University of Chicago ### 894418###Speaker#########
Speaker: Kiran K. Turaga, MD, MPH – University of Chicago
C
Career Development Workshop

Favorite

T. Clark Gamblin, MD, MS, MBA – Medical College of Wisconsin ### 917900###Moderator
Chair Lecture: The Roadmap of Value-Based Leadership

Favorite

T. Clark Gamblin, MD, MS, MBA – Medical College of Wisconsin ### 917900###Speaker
Clinical Trials for Peritoneal Metastases and Emerging Trends Session

Favorite

Colette R. Pameijer, MD – Penn State Cancer Institute ### 915784###Moderator @@@ Charles A. Staley, MD – Emory ### 915797###Moderator
Colon and Appendiceal Cancer Organoids for Comparison of Ex-Vivo Efficacy of Mitomycin C and Oxaliplatin Perfusion Regimens (AR7)

Favorite

Steven Forsythe, MSc – Wake Forest University ### 915761###Oral Abstract Presenter AR7
Colon Cancer with Peritoneal Metastasis: a National Cancer Database Analysis of Treatment Sequencing Trends (PM7)

Favorite

Braden Jensen, MD – University of Iowa ### 915769###Oral Abstract Presenter PM7
Current Adjuvant Therapy Use in the Setting of Sentinel Node Positivity for Melanoma (M1)

Favorite

Norma E. Farrow, MD – Duke University ### 915760###Oral Abstract Presenter M1
Cytoreductive Surgery in Selected Patients with Metastatic Gastric Cancer Treated with Systemic Chemotherapy (PM10)

Favorite

Yaniv Berger, MD – University of Chicago ### 915755###Oral Abstract Presenter PM10
D
Debate: HIPEC in Ovarian Cancer in the US

Favorite

Stephanie L. Wethington, MD, MSc – Johns Hopkins University School of Medicine ### 934672###Lecturer @@@ Oliver Zivanovic, MD – Memorial Sloan Kettering Cancer Center ### 937284###Lecturer
Defining ‘Complete Cytoreduction’ after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis (PM5)

Favorite

Carlos A. Munoz-Zuluaga, MD – Mercy Medical Center ### 915781###Oral Abstract Presenter PM5
Definition and Prediction of Early Recurrence and Mortality Following CRS HIPEC: Predicting Futility Preoperatively (PM11)

Favorite

Caroline Rieser, MD – University of Pittsburgh Medical Center ### 915790###Oral Abstract Presenter PM11
Developing Prospective Databases and Collaborations

Favorite

Shishir K. Maithel, MD – Emory ### 917909###Speaker
E
Establishing Novel Mutation Subtypes in Peritoneal Carcinomatosis of Appendiceal Origin (AR2)

Favorite

Mary Garland-Kledzik, MD – John Wayne Cancer Institute ### 915763###Oral Abstract Presenter AR2
Exosomal microRNA in Peritoneal Fluid as a Biomarker of Peritoneal Metastases from Gastric Cancer (AR4)

Favorite

Joji Kitayama, MD, PhD – Jichi Medical University ### 915771###Oral Abstract Presenter AR4
Exosomes as a Novel Immunotherapeutic Approach for Metastatic Ovarian Cancer Treatment (PM16)

Favorite

Simone Pisano, MS – Houston Methodist Research Institute ### 915785###Oral Abstract Presenter PM16
Expanded Mutation Profiling in Appendix Peritoneal Metastasis Has Prognostic and Therapeutic Utility When Managed with Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (AR1)

Favorite

Chunmeng Zhang, MD – University of Nebraska Medical Center ### 915806###Oral Abstract Presenter AR1
F
Failure to Thrive Following CRS-HIPEC: Causes and Consequences (PM8)

Favorite

Caroline Rieser, MD – University of Pittsburgh Medical Center ### 915790###Oral Abstract Presenter PM8
Finding Allies for your HIPEC Program

Favorite

Laura Lambert, MD – Huntsman Cancer Institute, University of Utah ### 915773###Speaker
Finding the Right Job and Creating Value: Two Perspectives

Favorite

H. Richard Alexander, Jr., MD – Rutgers Cancer Institute ### 917895###Speaker @@@ Oliver Eng, MD – University of Chicago ### 917899###Speaker
G
Genetic Signatures Can Identify Appendiceal Cancer Patients with Poor Outcomes Who Would Less Likely Benefit From Incomplete Cytoreduction/HIPEC (AR3)

Favorite

Omeed Moaven, MD – Wake Forest University ### 915779###Oral Abstract Presenter AR3
H
How to Manage Your Time: Emails, Appointments and More

Favorite

Jonathan S. Zager, MD – H. Lee Moffitt Cancer Center ### 917915###Speaker
How to Say No

Favorite

Laura Lambert, MD – Huntsman Cancer Institute, University of Utah ### 915773###Speaker
HPB Session 1

Favorite

Alexandra Gangi, MD – Cedars Sinai Medical Center ### 915762###Moderator @@@ Sepideh Gholami, MD – University of California Davis Health ### 915764###Moderator
I
Impact of Enhanced Recovery after Surgery Program on Postoperative Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (PM4)

Favorite

George Salti, MD – Edward-Elmhurst Health ### 915791###Oral Abstract Presenter PM4
Impact of Socioeconomic Status on Outcomes in Colorectal Cancer with Peritoneal Metastases (PM1)

Favorite

Caroline Rieser, MD – University of Pittsburgh Medical Center ### 915790###Oral Abstract Presenter PM1
Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent HAI and Systemic Chemotherapy for Colorectal Liver Metastases (HPB2)

Favorite

John M. Creasy, MD – Duke University Medical Center ### 915759###Oral Abstract Presenter HPB2
Inhibition of Neutrophil Extracellular Traps (NETs) with Chloroquine Reduces Peritoneal Metastatic Tumor Burden (AR5)

Favorite

Pavan Rao, MD – Allegheny General Hospital ### 915787###Oral Abstract Presenter AR5
International Comparison of Oncologic Outcomes after Isolated Limb Infusion (ILI) for Advanced Melanoma (M5)

Favorite

Michael J. Carr, MD, MS – Moffitt Cancer Center ### 918093###Oral Abstract Presenter#########
Oral Abstract Presenter: Michael J. Carr, MD, MS – Moffitt Cancer Center
M5
International Multi-Center Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients (M4)

Favorite

Hidde M. Kroon, MD, PhD – Royal Adelaide Hospital ### 915772###Oral Abstract Presenter#########
Oral Abstract Presenter: Hidde M. Kroon, MD, PhD – Royal Adelaide Hospital
@@@ Michael J. Carr, MD, MS – Moffitt Cancer Center ### 918093###Oral Abstract Presenter#########
Oral Abstract Presenter: Michael J. Carr, MD, MS – Moffitt Cancer Center
M4
Interventional Radiology (Embolization)

Favorite

Riad Salem, MD – Northwestern University ### 917912###Speaker
Intraperitoneal CMP-001, A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancers (AR6)

Favorite

Carlos HF Chan, MD, PhD – University of Iowa Hospitals and Clinics ### 915756###Oral Abstract Presenter AR6
Invited Lecture: Advances in Neoadjuvant Therapy for Locoregionally Advanced Melanoma: Implications for Clinical Practice and Future Research

Favorite

Ahmad Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and Research Institute ### 917913###Speaker
Invited Lecture: CAR-T Cell Regional Delivery Approaches

Favorite

Steven Katz, MD – Roger Williams ### 917908###Speaker
Is There Benefit from Hyperthermic Intraperitoneal Chemotherapy in Advanced Gastric Cancer: Early Results from a Phase II Clinical Trial (CT4)

Favorite

James D. McDonald, MD – NIH / Surgical Oncology Program ### 915778###Oral Abstract Presenter CT4
Isolated Limb Perfusion as an Effective Treatment Modality for Locally Advanced Kaposi Sarcoma of the Extremities (M6)

Favorite

Winan van Houdt, MD, PhD – Netherlands Cancer Institute ### 915789###Oral Abstract Presenter M6
L
Lecture: The ECOG HIPEC Working Group and Working with Cooperative Groups like ECOG

Favorite

Peter J. O'Dwyer, MD – University of Pennsylvania and the Abramson Cancer Center ### 917910###Speaker
Long-Term Normothermic Intraperitoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastasis: Results from Clinical Trials Over a Decade in Japan (CT3)

Favorite

Hironori Yamaguchi, MD, PhD – Jichi Medical University ### 915805###Oral Abstract Presenter CT3
M
Medical Oncology

Favorite

Daniel M. Halperin, MD – University of Texas MD Anderson Cancer Center ### 917901###Speaker
Melanoma Case Presentation

Favorite

Tariq Almerey, MD – Mayo Clinic Florida ### 953887###Presenter
Melanoma Case Presentation Tumor Board

Favorite

Jonathan S. Zager, MD – H. Lee Moffitt Cancer Center ### 917915###Panelist @@@ Ahmad Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and Research Institute ### 917913###Panelist @@@ Giorgos Karakousis, MD – University of Pennsylvania ### 915770###Panelist @@@ Georgia Beasley, MD, MHSc – Duke University ### 938016###Panelist
Melanoma Session 1

Favorite

Giorgos Karakousis, MD – University of Pennsylvania ### 915770###Moderator @@@ Joseph Skitzki, MD – Roswell Park Cancer Institute ### 915796###Moderator
Mentor/Mentee Session

Favorite

Fabian M. Johnston, MD MHS – Johns Hopkins University ### 917904###Speaker
Metastatic Neuroendocrine Tumor Confined to the Liver

Favorite

Sepideh Gholami, MD – University of California Davis Health ### 915764###Moderator @@@ Alexandra Gangi, MD – Cedars Sinai Medical Center ### 915762###Moderator
Mismatch Repair Deficiency is Associated with Worse Survival in Colorectal/Appendiceal Cancers with Peritoneal Metastases (PM17)

Favorite

Scott K. Sherman, MD – University of Iowa Carver College of Medicine ### 915795###Oral Abstract Presenter PM17
P
Panel Discussion and Q&A

Favorite
Patient KG

Favorite

Adrienne N. Bruce, MD – Department of Surgery, Hospital of the University of Pennsylvania ### 936605###Presenter
PD-L1 Expression is Altered in Malignant Peritoneal Mesothelioma Patients after Chemotherapy and HIPEC (AR8)

Favorite

Lai Xue, MD – University of Chicago ### 915804###Oral Abstract Presenter AR8
Pediatric HIPEC

Favorite

Andrea HAYES-JORDAN, MD – UNC Chapel Hill ### 917902###Speaker
Perineural Spread of Metastatic Melanoma in the Femoral Nerve

Favorite

Michael J. Carr, MD, MS – Moffitt Cancer Center ### 918093###Presenter#########
Presenter: Michael J. Carr, MD, MS – Moffitt Cancer Center
Peritoneal Cell-Free Tumor DNA as a Biomarker of Disease Burden in Peritoneal Carcinomatosis (PM18)

Favorite

Katie M. Leick, MD, MS – University of Iowa ### 915775###Oral Abstract Presenter PM18
Peritoneal Metastases Session 1

Favorite

Harveshp Mogal, MD, MS, FACS – Medical College of Wisconsin ### 915780###Moderator @@@ Melanie Ongchin, MD – University of Pittsburgh School of Medicine ### 915783###Moderator
Peritoneal Metastases Session 2

Favorite

Jordan Cloyd, MD – The Ohio State University ### 915758###Moderator#########
Moderator: Jordan Cloyd, MD – The Ohio State University
@@@ Ugwuji N. Maduekwe, MD MMSc FACS – University of North Carolina at Chapel Hill ### 915776###Moderator#########
Moderator: Ugwuji N. Maduekwe, MD MMSc FACS – University of North Carolina at Chapel Hill
Peritoneal Metastases Session 3

Favorite

Richelle T. Williams, MD, MS – University of Maryland ### 915801###Moderator @@@ Danielle Bischof, MD MHS FRCSC FACS – Sinai Health System ### 955460###Moderator
Peritoneal Metastases Session 4

Favorite

Jonathan Greer, MD – Johns Hopkins University School of Medicine ### 915765###Moderator @@@ Ashley M. Holder, MD, FACS – Houston Methodist Hospital ### 915766###Moderator
Phase I Trial of Intraperitoneal Oxaliplatin in Combination with Intravenous FOLFIRI for Unresectable Peritoneal Carcinomatosis from Colorectal and Appendiceal Cancer (CT1)

Favorite

Laura Lambert, MD – Huntsman Cancer Institute, University of Utah ### 915773###Oral Abstract Presenter CT1
Q
Quality Analysis of Operative Reports and Referral Data for Appendiceal Peritoneal Carcinomatosis (PM12)

Favorite

Christopher W. Mangieri, MD – Wake Forest University Baptist Medical Center ### 915777###Oral Abstract Presenter PM12
R
Regionally Advanced Melanoma at Presentation: A Role for Neoadjuvant Therapy?

Favorite

Colby Tyler – Lenoir Rhyne University ### 938014###Presenter
Role of Intraoperative Margin Treatment for Resection of Colorectal Liver Metastases (HPB3)

Favorite

Tracey Pu, BS – Wake Forest School of Medicine ### 915786###Oral Abstract Presenter HPB3
S
Safety and Efficacy of Peptide Receptor Radionucleotide Therapy (PRRT) in Metastatic Neuroendocrine Tumors: A US Single-Institution Experience Post-FDA Approval (HPB4)

Favorite

Erin A. Strong, MD, MBA – Medical College of Wisconsin ### 915798###Oral Abstract Presenter HPB4
Starting a HIPEC Program in an Academic Center

Favorite

Charles A. Staley, MD – Emory ### 915797###Speaker
Starting a HIPEC Program in the Community or Private Practice Setting

Favorite

Sharmila Roy Chowdhury, MD – Southwest Cancer Surgery ### 917911###Speaker
Starting a HIPEC Program in the Shadow of a Large HIPEC Program

Favorite

Colette R. Pameijer, MD – Penn State Cancer Institute ### 915784###Speaker
Steps for Publishing Success

Favorite

T. Clark Gamblin, MD, MS, MBA – Medical College of Wisconsin ### 917900###Speaker
Surgery

Favorite

James R. Howe, MD – University of Iowa ### 917903###Speaker
Surgical Phenotype of Patients with Malignant Peritoneal Mesothelioma and Germline Mutation (PM9)

Favorite

Yaniv Berger, MD – University of Chicago ### 915755###Oral Abstract Presenter PM9
T
Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: A Multi-Institutional Experience (M3)

Favorite

James Sun, MD – Moffitt Cancer Center ### 915799###Oral Abstract Presenter M3
The Hidden Length of Stay following Cytoreductive Surgery/HIPEC: Risk Factors for Unplanned 90-Day Readmission (PM2)

Favorite

Robert J. Torphy, MD – University of Colorado ### 915800###Oral Abstract Presenter PM2
Travel Distance and the Impact on Post-Surgical Outcomes and Overall Survival after CRS/HIPEC. A Study from the US HIPEC Collaborative (PM3)

Favorite

Bernardo M. Pessoa, MD – Johns Hopkins University ### 926139###Oral Abstract Presenter PM3
Treatment Variation and Long-Term Outcomes of Appendiceal Neoplasms (PM13)

Favorite

Christopher Scally, MD, MS – University of Texas MD Anderson Cancer Center ### 915792###Oral Abstract Presenter PM13
Two cases with panel discussion

Favorite

Alexandra Gangi, MD – Cedars Sinai Medical Center ### 915762###Moderator @@@ Sepideh Gholami, MD – University of California Davis Health ### 915764###Moderator
U
Update: CRS versus CRS/HIPEC in Colon Cancer Peritoneal Metastases

Favorite

Jason Foster, MD – University of Nebraska Medical Center ### 925554###Speaker
W
What Drives High Cytoreductive Surgery and HIPEC Costs: Patient, Provider or Tumor? (PM6)

Favorite

Patrick B. Schwartz, MD – University of Wisconsin School of Medicine and Public Health ### 915793###Oral Abstract Presenter PM6